Ambu Announces: Ready to Launch its New Display Technology for Single-Use Endoscopy

Ambu announced today that the Ambu® aView™ 2 Advance has now obtained CE mark and is listed at Food and Drug Administration which enables release for sale in Europe and North America by mid-May 2020.

The aView 2 Advance is a portable full-HD display unit to be used together with our single-use endoscopes across multiple clinical specialties. Ambu, is a global manufacturer of medical devices, including single-use endoscopes.

“We have pioneered single-use endoscopy for more than ten years, and we now bring our portfolio to a new level of sophistication,” said Juan Jose Gonzalez, CEO of Ambu. “Image quality is critical for healthcare providers and patient diagnosis, and we can now offer a display unit that was not possible with a single-use endoscope just a few years ago. I believe we are raising the bar on innovative technology for hospitals and clinics.”

Jens Kemp, Ambu USA’s Vice President of Marketing said, the aView 2 Advance will fit the needs of clinicians throughout the hospital.

“Its mobile platform not only works well within the ICU, but specialists from other areas can use it to perform everything from cystoscopies to flexible laryngoscopies to bronchoscopies,” Kemp said. “It will increase workflow, efficiency and enable clinicians to address patients quickly.”

A reusable display for single-use devices

The aView 2 Advance is the display unit that clinicians connect a single-use scope into in order to transmit a live image from inside the human body. The scope is single-use and is discarded when the procedure is done – for hygienic, practical and economic reasons – while the display unit is reused as it has not been in contact with the patient.

“The aView 2 Advance seamlessly connects to the aScope family of sterile, single-use flexible endoscopes,” Kemp said. “A live image is displayed within seconds of powering on the monitor providing a high-quality image, with image capture and recording capability, in an easy to use, transportable monitor solution. After the procedure, health care providers can simply clean the monitor using commercially available disinfectant wipes widely used in healthcare.”

Technology for future product development

The aView 2 Advance covers Ambu’s existing endoscopes, which means that it can be used with a bronchoscope (for airway procedures), a rhinolaryngoscope (for ENT procedures) or a cystoscope (for urology procedures). The unit offers full-HD resolution, advanced image processing and an anti-reflective touchscreen. In addition, aView 2 Advance enables users to transfer recorded data to the hospital’s electronic health records (EHR).

The display unit is part of Ambu’s expansion across all major areas of endoscopy, and this technology platform will form the basis for the development of Ambu’s future single-use endoscope devices.

Built on a decade of experience

Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. Ten years later, in 2019, over 600,000 Ambu single-use endoscopes were used in more than 3,500 hospitals making Ambu the world’s largest supplier of single-use endoscopes.

SourceAmbu

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”